Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
$9.96-17.82%
报价 2026-11-13
市值
$1.71B
EV
$2.18B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -27.0%
$5.44$13.65
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| VIRVir Biotechnology, Inc. | $1.71B | -17.8% | +1488.5% | 97.2% | – | – | – | |
| IOVAIovance Biotherapeutics, Inc. | $3.59B | +1.7% | +62.6% | 48.4% | – | – | – | |
| MRVIMaravai LifeSciences Holdings, Inc. | $2.14B | -1.8% | +16.0% | 34.6% | – | – | – | |
| REPLReplimune Group, Inc. | $2.08B | -0.4% | +763.6% | 0% | – | – | – | |
| PRMEPrime Medicine, Inc. | $776.8M | +9.8% | +84.0% | -1,025.6% | – | – | – | |
| KURAKura Oncology, Inc. | $713.9M | +4.6% | +5.9% | 94.7% | – | – | – | |
| GERNGeron Corporation | $623M | -2.7% | +26.3% | 66.7% | – | – | – | |
| DNAGinkgo Bioworks Holdings, Inc. | $623M | -6.1% | -49.7% | 84.6% | – | – | – | |
| LENZLENZ Therapeutics, Inc. | $129.8M | +1.0% | -2.6% | 80.2% | – | – | – | |
| 同行中位数 | – | – | +21.1% | 57.6% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。